" class="no-js "lang="en-US"> Daewoong Pharmaceutical - Medtech Alert
Wednesday, June 19, 2024
Daewoong Pharmaceutical | MTA

Daewoong Pharmaceutical

About Daewoong Pharmaceutical

Daewoong Pharmaceutical

Related Story

HanAll Biopharma and Daewoong Pharmaceutical Enter into Co-Development Agreement with NurrOn Pharmaceuticals to Develop Therapy for Parkinson's Disease

May 25 2023

HanAll Biopharma and Daewoong Pharmaceutical announced that they have entered into a co-development agreement with NurrOn […]

Daewoong Pharmaceutical Announce Publication of Phase 3 Study of 'Envlo', a New Treatment for Diabetes

April 24 2023

The research results of a Daewoong Pharmaceutical SGLT-2 inhibitor new drug for diabetes, ‘Envlo’, have been […]

Daewoong Pharmaceutical and Sygnature Discovery Announce Drug Discovery Research Collaboration

April 18 2023

Daewoong Pharmaceutical has entered a research collaboration with Sygnature Discovery to expand its global open […]

M8 Pharmaceuticals and Daewoong Pharmaceutical Sign Exclusive Licensing Agreement for Envlo™ for Brazil and Mexico

February 28 2023

M8 Pharmaceuticals and Daewoong Pharmaceuticals announced they have signed an exclusive licensing agreement whereby M8 […]

Daewoong Pharmaceutical Begins the First Administration of the Bersiporocin, a New Treatment for Idiopathic Pulmonary Fibrosis

February 6 2023

The world’s first-in-class candidate substance against idiopathic pulmonary fibrosis, ‘Bersiposocin‘ (DWN12088), which is under the […]